Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S5WG
|
|||
| Former ID |
DAP001542
|
|||
| Drug Name |
Flucytosine
|
|||
| Synonyms |
Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Endocarditis [ICD-11: BB40-BA42; ICD-10: I38; ICD-9: 421] | Approved | [1], [2] | |
| Therapeutic Class |
Antifungal Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H4FN3O
|
|||
| Canonical SMILES |
C1=NC(=O)NC(=C1F)N
|
|||
| InChI |
1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
|
|||
| InChIKey |
XRECTZIEBJDKEO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2022-85-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
405592, 602763, 841044, 1434447, 3140368, 3218074, 5270497, 5329900, 5431724, 6041883, 7847389, 7979233, 8139861, 11112505, 11404488, 11466962, 11468082, 11486773, 11564865, 14747633, 15194483, 24712291, 24870520, 24894919, 24894928, 26719629, 29222501, 39910157, 46386766, 46504735, 47662407, 47736597, 48110551, 48110552, 48416018, 49699216, 49831643, 49960195, 51074762, 53653662, 56424024, 57321755, 57930982, 81041221, 83591697, 85086121, 87570095, 87633378, 88817477, 92125834
|
|||
| ChEBI ID |
CHEBI:5100
|
|||
| ADReCS Drug ID | BADD_D00913 | |||
| SuperDrug ATC ID |
D01AE21; J02AX01
|
|||
| SuperDrug CAS ID |
cas=002022857
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli Nissle 1917
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase activity | |||
| Description | 5-fluorocytosine can be metabolized by Escherichia coli Nissle 1917, which results in the increase of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4], [5] | |||
| Metabolic Reaction | Deamination | |||
| Resulting Metabolite | 5-fluorouracil | |||
| Metabolic Effect | Increase activity; Increase toxicity | |||
| Description | Flucytosine can be metabolized to 5-fluorouracil by gut microbiota through deamination, which results in the increase of drug's activity and toxicity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lactobacillus paracasei was decreased by Flucytosine (adjusted p-values: 7.45E-03). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015 Sep 29;5:14554. | |||
| REF 4 | The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2016;12(1):31-40. | |||
| REF 5 | CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004 Feb;34(2):336-44. | |||
| REF 6 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.